三叶草生物：与国光生技终止合作

Core Viewpoint - The company announced the termination of its exclusive agreement with Guoguang Biotech, effective June 30, 2025, which will result in the cessation of distribution of the quadrivalent seasonal influenza vaccine in mainland China. The board believes this termination will not have a significant adverse impact on the group's operations, as it will continue to advance the research and development of its proprietary respiratory syncytial virus (RSV) candidate vaccine SCB-1019 [1] Group 1 - The exclusive agreement with Guoguang Biotech will end on June 30, 2025 [1] - The company will no longer distribute the quadrivalent seasonal influenza vaccine in mainland China after the agreement termination [1] - The board of directors believes that the termination will not significantly adversely affect the group's operations [1] Group 2 - The company will continue to pursue the research and development of its proprietary RSV candidate vaccine SCB-1019 [1]